Samrat Pharmachem Ltd

Samrat Pharmachem Limited reported a disastrous fourth quarter for FY2026, posting a net loss of ₹2.04 crores compared to a loss of ₹0.40 crores in the same quarter last year—a staggering deterioration of 410.00%. The micro-cap pharmaceutical chemicals manufacturer, with a market capitalisation of ₹65.00 crores, saw its stock plummet 15.63% to ₹210.00 on June 01, 2026, as investors reacted to the alarming financial performance that marked the company's worst quarterly showing in recent history.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 May 2026, providing investors with the latest insights into its performance and prospects.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook.

For the fifth consecutive session, Samrat Pharmachem Ltd closed lower, hitting a fresh 52-week low of Rs 194.4 on 30 Mar 2026. This decline comes amid a broader market that has shown some resilience, underscoring the stock's persistent underperformance.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Samrat Pharmachem Ltd has witnessed a significant shift in its valuation parameters, with key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios deteriorating sharply compared to historical averages and peer benchmarks. This change has coincided with a steep decline in the stock price, prompting a downgrade in its investment grade to Strong Sell by MarketsMOJO as of 19 Aug 2025.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with the latest insights into its performance and outlook.

Samrat Pharmachem Ltd’s valuation metrics have recently deteriorated, shifting from expensive to very expensive territory, raising concerns about its price attractiveness amid a challenging sector backdrop and subdued returns relative to benchmarks.

Samrat Pharmachem Ltd’s stock touched a fresh 52-week low of Rs.195.1 today, marking a significant decline amid ongoing challenges in its financial performance and market positioning. This new low reflects a continuation of the stock’s downward trajectory over the past year, with the share price now trading well below all key moving averages.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Samrat Pharmachem Ltd’s stock reached a fresh 52-week low of Rs.199 today, marking a significant decline amid ongoing challenges in the Pharmaceuticals & Biotechnology sector. The stock has underperformed its sector peers and benchmark indices, reflecting persistent pressures on the company’s financial and market metrics.

Samrat Pharmachem Ltd’s stock declined to a fresh 52-week low of Rs.206 on 21 Jan 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have underperformed both its sector and the broader market, reflecting persistent pressures on its financial and market performance.